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Abstract 
 
Changes in temporomandibular joint sounds after  
botulinum toxin injection into masticatory muscles 
 
A-Young Chung 
 
Department of Dentistry 
The Graduate School, Yonsei University 
 
(Directed by Professor Seong-Taek Kim, D.D.S., Ph.D.) 
 
Temporomandibular joint (TMJ) sounds such as clicking/popping or crepitus 
that are not associated with any pain and do not affect the movement of joint do 
not need to be treated. And conservative treatments are not successful in 
reducing the sounds generally. However, some patients find such joint sounds 
themselves to be very distressing. 
This study looked at patients who received botulinum toxin (BoNT) injection 
into their masseter and/or temporalis muscles for treatment of myofascial pain, 
bruxism, clenching, or chronic migraine. To identify the related factors 
underlying changes in production of TMJ sounds, patients who ceased producing 
TMJ sounds were compared to those who continued producing TMJ sounds 
following BoNT injection. 
v 
This study found that only the degree of cheek ridging differed significantly 
between the groups. This suggests that weakening the intensity of masticatory 
muscle contraction by BoNT injection could be responsible for reducing TMJ 
sounds by decreasing the joint loading or microtrauma. BoNT injection into the 
masseter and/or temporalis muscles may reduce distressing TMJ sounds and 
serve as an alternative treatment for patients who have moderate to severe 
cheek ridging. However, since this study was subject to several limitations, the 
results need to be confirmed in future well-controlled prospective studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                          
Keywords: botulinum toxin A, cheek ridging, masticatory muscle,  
temporomandibular joint sound  
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Changes in temporomandibular joint sounds after  
botulinum toxin injection into masticatory muscles 
 
A-Young Chung 
 
Department of Dentistry 
The Graduate School, Yonsei University 
 
(Directed by Professor Seong-Taek Kim, D.D.S., Ph.D.) 
 
 
I. INTRODUCTION 
 
Temporomandibular disorders (TMDs) are common musculoskeletal 
conditions that cause pain and disability in the orofacial region and can be 
classified into temporomandibular joint (TMJ) disorders and muscle disorders 
(Schiffman et al., 2014). TMJ dysfunction usually presents as a disruption of the 
normal disc-condyle movement, producing joint sounds such as clicking, 
popping, and crepitus (Okeson, 2013, 137). According to the Diagnostic Criteria 
for Temporomandibular Disorders (DC/TMD, 2014), clicking or popping sounds 
may occur with disc displacement with reduction (DDwR), and crepitus can be 
detected in degenerative joint disease (Schiffman et al., 2014). DDwR can result 
in decreased joint space that subsequently results in enhanced degrees of 
arthritis and condylar resorption (Kurtoglu et al., 2008). 
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A joint sound that is not associated with any pain and does not affect the 
movement of joint does not need to be treated (Okeson, 2013, 323). However, 
some patients find such joint sounds themselves to be very distressing. 
TMJ sounds do not generally disappear with conservative treatments including 
therapeutic exercises and splint treatment (Vichaichalermvong et al., 1993). 
Only a few randomized controlled trials (RCTs) have investigated the treatment 
effects of DDwR (Naeije et al., 2012). The RCT study by Yoda et al. (2003) 
found that, a therapeutic mouth-opening and mouth-closing exercises for 
maintaining the disc repositioning mandibular position on the painless reciprocal 
clicking of DDwR diagnosed by magnetic resonance imaging (MRI) significantly 
reduced the clicking sound compared with a no-treatment group. However, a 
recaptured disc was only seen on MRI in a minority of the cases with clicking 
reduction, and no convincing explanation of the exact mechanism underlying this 
reduction was provided (Yoda et al., 2003). In two RCT studies, Lundh 
compared the short-term effects of an anterior repositioning splint (Lundh et 
al., 1985) and disc-repositioning onlays (Lundh et al., 1988) with the effects of 
a flat occlusal splint and a no-treatment group. The results showed that anterior 
repositioning splints or onlays could reduce or even eliminate reciprocal clicking 
for as long as they were used (which was for 6 weeks and 6 months, 
respectively, in that study). However, reciprocal clicking recurred within 6 
weeks after removing the anterior repositioning splints or onlays. Also, flat 
occlusal splints did not eliminate the reciprocal clicking. In a double-blind, 
controlled RCT, Conti et al. (2006) compared the efficacies of three treatments 
for patients who experience painful joint clicking interventions: (1) a modified 
(bilaterally balanced) stabilization splint, (2) a conventional stabilization splint 
with canine guidance, and (3)a nonoccluding splint. The entire sample showed a 
reduction in the frequency of joint clicking while wearing oral splints, with no 
significant differences among the groups. However, changes in clicking after 
removing the oral splints were not evaluated. The effects of intra-articular 
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(upper joint space) injection of sodium hyaluronate were compared with the 
effects of physiologic saline in two RCT studies (Bertolami et al., 1993; 
Hepguler et al., 2002). Bertolami et al. (1993) reported significant 
improvements in the perceived noise level [visual analog scale (VAS)] and the 
frequency of noise occurrence for the hyaluronate group compared with the 
placebo group. Moreover, Hepguler et al. (2002) detected improvement in the 
sound intensity (as measured using VAS) induced by two intra-articular 
injections of hyaluronate. However, the objective effects of injecting sodium 
hyaluronate on DDwR are difficult to interpret.  
A few studies have suggested that botulinum toxin (BoNT) treatment can be 
effective against TMJ sounds (Bakke et al., 2005; Emara et al., 2013), DDwR, 
and TMJ dislocation (Bouso et al., 2010; Fu et al., 2010; Martínez-Pé rez and 
García Ruiz-Espiga, 2004; Mendes and Upton, 2009). Most of these studies 
have injected BoNT into the lateral pterygoid muscles, which appear to be 
responsible for TMJ clicking (Emara et al., 2013), or DDwR (Wongwatana et al., 
1994). Bakke et al. (2005) assumed that BoNT injection provides transient 
chemodenervation and reduces the function of the lateral pterygoid muscle by 
blocking the gamma motor neurons supplying the muscle spindles in the lateral 
pterygoid. Those studies showed slight improvements in the disc-condyle 
relationship and reduction of the clicking sound. However, the precise 
underlying mechanisms were unclear. Also, none of the studies included 
controls, and all had small samples and short follow-up periods.  
In contrast, BoNT injection into the masticatory closing muscles (masseter 
and/or temporalis muscles) has been more generally proposed as an effective 
treatment option for TMD, bruxism, and masseter hypertrophy (Kurtoglu et al., 
2008), as well as for other approved indications including chronic migraine. 
However, there have been no reports of changes in TMJ sounds in those 
conditions. BoNT injection into the masticatory closing muscles can be expected 
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to reduce the intra-articular pressure and resistance during mouth opening (or 
reducing the displaced disc), and thereby affect the joint sounds. 
This study looked at patients who received BoNT injection into their masseter 
and/or temporalis muscles for treatment of myofascial pain, bruxism, clenching, 
or chronic migraine. To identify the related factors underlying changes in 
production of TMJ sounds, patients who ceased producing TMJ sounds were 
compared to those who continued producing TMJ sounds following BoNT 
injection. 
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II. SUBJECTS AND METHOD 
 
This study performed a retrospective chart review of patients with myofascial 
pain, parafunctional habits such as bruxism or clenching, or chronic migraine 
who had been injected with BoNT (Botox, Allergan, Irvine, United States of 
America (USA)) between June 2013 and October 2014 at the Department of 
Orofacial Pain and Oral Medicine, College of Dentistry, Dental Hospital of Yonsei 
University.  
In total, 102 patients were injected with BoNT during the study period. The 
patients were initially screened to ensure that they had a record of a repeated 
visit at least once during the follow-up period of 1-3 months after the injection. 
This initial screening resulted in 57 patients being excluded since they did not 
revisit the clinic or the chart records of their conditions were incomplete. The 
remaining 55 patients were reviewed by checking their chart records for TMJ 
sounds (clicking, popping, or crepitus) during active mouth opening (AMO) before 
the injection. This resulted in the further exclusion of 27 patients who exhibited 
no TMJ sounds preinjection. Therefore, 28 patients were finally included, and 
their chart records were reviewed for TMJ sounds detected during AMO at least 
once during the follow-up period of 1-3 months after the injection.  
The TMJ sounds during AMO did not change in making sound postinjection in 
18 patients (group A), while they disappeared in the other 10 patients (group 
B). In order to identify the related factors for a reduction in TMJ sounds, the 
several parameters were compared between groups A and B (see Table 1). 
Degenerative or pathologic bony change includes bony irregularity(erosion) or  
flattening of condylar bony surface, osteophyte formation, thickening of articular 
surface(osteosclerosis) and subchondral cyst in the subarticular bone (Okeson, 
2013, 208-209). The squareness of the face was evaluated using a facial 
photograph and a PA skull projection view. 
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BoNT was reconstituted with 2 ml of sterile saline to a concentration of 5 
units/0.1mL. A total of 50-60 units of BoNT was injected into the bilateral 
masseter muscles, and/or 30-40 units of BoNT was injected into the bilateral 
temporalis muscles.  
 
Table 1. Parameters compared between groups A and B 
 
a
Type of temporomandibular joint (TMJ) sound (clicking/popping and crepitus)  
Age 
Sex  
Total dose of botulinum toxin (BoNT; in units) injected into the masseter and 
temporalis muscles 
b
Degree of active mouth opening (AMO) (mm)  
c
Site of subjective pain during AMO  
d
Degree of tenderness to palpation of the masseter and temporalis muscles and TMJ  
e
Occlusion
 
Degree of overjet (OJ) (mm) 
Degree of overbite (OB) (mm) 
Total number of centric occlusion (CO) stops 
Bilateral balance of CO stop (this was considered to be balanced 
when numbers of stops on the right and left sides differed by less 
than 2) 
f
Anatomic 
muscular and 
skeletal 
pattern 
Squareness of the face, as evaluated in a facial photograph and a 
posteroanterior (PA) skull projection view (subjective evaluation of 
the degree of squareness by one examiner) 
g
Bony change 
Degenerative or pathologic bony change in the condylar head in 
computed tomography (CT) or cone-beam CT (CBCT) images of the 
temporomandibular joint (TMJ) 
h
Parafunctional 
habit
 
Subjective (self-aware or heard by others) parafunctional habits 
such as clenching and bruxism during daytime and/or nighttime 
Degree of cheek and tongue ridging 
a,b,c
: at preinjection  and postinjection  
d,e,f,g,h
: at preinjction  
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III. STATISTICAL ANALYSIS 
 
The results were analyzed with SPSS (version20.0, SPSS, Chicago, Illinois, 
USA). The independent t-test was used to compare the total number of CO 
stops, degree of OJ, OB, and AMO (all in mm), and total dose of BoNT injected 
into the masseter and temporalis muscles. Differences between the groups were 
assessed by applying the chi-square test (Fisher’s exact test) to the following 
parameters: the bilateral balance of CO stops, the degree of tenderness to 
palpation on the masseter and temporalis muscles and TMJ, the site of 
subjective pain during AMO, the squareness of the face, degenerative or 
pathologic bony change in the condylar head, subjective parafunctional habits, 
and the degree of cheek and tongue ridging. Differences with a probability value 
of less than 0.05 were considered statistically significant.  
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IV. RESULTS 
 
Before the injection, 16 subjects (88.9%) in group A had clicking, one 
(5.55%) had crepitus, and one (5.55%) had both crepitus and clicking. One 
subject who had only clicking before the injection had both clicking and crepitus 
after the injection during the follow-up period (1-3 months). While another 
subject showed the opposite result, with both clicking and crepitus before the 
injection and only clicking after the injection. There were no changes in the type 
of joint sound in the other subjects in group A. In group B, eight subjects 
(80.0%) had clicking (6)/popping (2), and two (20%) had crepitus during AMO 
at preinjection (Figure 1). 
 
 
Figure 1. Changes in temporomandibular joint (TMJ) sounds in groups A and B 
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The age of the subjects was 35.94 ± 8.49 years (mean±SD; range, 25 to 52 
years) in group A (all females) and 32.70 ± 6.94 years (range, 23 to 42 years) 
in group B (eight females and two males).  
The results presented in Table 2 indicate that there were no significant 
differences between groups A and B in age, the total dose of BoNT injected into 
the masseter and temporalis muscles and degree of AMO at pre- and 
postinjection, OJ and OB and the total number of CO stops at preinjection. The 
bilateral balance of CO stops had no significant differences (Table 3).  
Comparison of the squareness of the face revealed the most frequent type in 
group A to be moderate face squareness (n=12, 66.7%) and in group B, to be 
severe face squareness (n=7, 70%); however, this difference was not 
statistically significant (Table 4). There were also no significant differences in 
the degree of tenderness to palpation on the masseter and temporalis muscles 
and TMJ at preinjection (Table 5), or the location of subjective pain during AMO 
at pre- and postinjection (Table 6) between the two groups.  
With regard to degenerative or pathologic bony change in the condylar head 
observed in CT/CBCT images of the TMJ, eight subjects (53.3%) in group A had 
normal condylar heads and seven (46.7%) showed pathologic bony changes 
(CT/CBCT was not performed on three subjects). CT/CBCT images were 
obtained in nine subjects in group B, of which two (22.2%) showed normal 
anatomy and seven (77.8%) showed condylar bony changes. There was no 
significant difference between groups A and B (P=0.210) (Table 7). Subjective 
(self-aware or heard by others) parafunctional habits such as clenching and 
bruxism during daytime and/or nighttime were reported by all 10 subjects in 
group B and 15 subjects (83.3%) in group A (Table 8). 
According to Table 9, the degree of cheek ridging differed significantly 
between the groups (P=0.022). Mild cheek ridging predominated in group A 
(n=13, 72.2%) while moderate cheek ridging predominated in group B (n=7, 
70%). Likewise, mild tongue ridging was frequent (n=12, 66.7%) in group A and 
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moderate tongue ridging was dominant (n=7, 70%) in group B. However, there 
were no significant group differences between these results (P=0.050).  
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Table 2. Group comparison of mean change in age, the total dose of BoNT 
(untis) injected into the masseter and temporalis muscles, the degree of AMO 
(mm) at pre- and postinjection, OJ (mm) and OB (mm) and total number of CO 
stops at preinjection 
 
 Group n Mean SD 
Independent 
t-test: P  
Age 
A 18 35.94 8.49 
0.313 
B 10 32.70 6.94 
BoNT dose into 
masseter muscles 
A 18 60.00 9.55 
0.431 
B 10 62.80 7.44 
BoNT dose into 
temporalis muscles 
A 18 37.78 7.32 
0.596 
B 10 36.20 7.68 
Degree of AMO  
at preinjection 
A 18 45.83 4.50 
0.911 
B 10 46.10 8.09 
Degree of AMO  
at postinjection 
A 18 45.78 4.54 
0.751 
B 9* 45.00 8.17 
Degree of OJ 
A 18 2.14 1.61 
0.719 
B 10 2.40 2.17 
Degree of OB 
A 18 1.59 1.78 
0.386 
B 10 2.20 1.75 
CO stops 
A 18 6.39 1.75 
0.864 
B 10 6.50 1.35 
*: No record for 1 subject 
 
 
 
 
Table 3. Group comparison of the bilateral balance of CO stops at preinjection 
 
 
 
 
 
 
 
 
 
*: this was considered to  be balanced when numbers of stops on the right and left sides 
differed by less than 2  
  Bilateral CO stops 
   Balance* Imbalance 
Group n n (%) n (%) 
A 18 14 (77.8) 4 (22.2) 
P=0.891 
B 10 8 (80) 2 (20) 
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Table 4. Distribution across the two groups in degree of face squareness at 
preinjection 
 
 
 
Table 5. Group comparison of the degree of tenderness to palpation at 
preinjection 
 
 
 
Table 6. Group comparison of the location of subjective pain during AMO at 
pre- and postinjection 
 
a
: No record for 1 subject, 
b
: No records for 2 subjects, 
c
: No records for 2 subjects 
 
  Degree  
  Mild Moderate Severe 
 
Group n n (%) n (%) n (%) 
Face 
squareness 
A 18 1 (5.6) 12 (66.7) 5 (27.8) 
P=0.050 
B 10 0 (0) 3 (30) 7 (70) 
Site 
  Tenderness to palpation 
   None Mild Moderate Severe 
Group n n (%) n (%) n (%) n (%) 
TMJ 
A 18 6 (33.3) 4 (22.2) 8 (44.4) 0 (0) 
P=0.271 
B 10 4 (40) 0 (0) 6 (60) 0 (0) 
Masseter 
A 18 2 (11.1) 4 (22.2) 11 (61.1) 1 (5.6) 
P=0.539 
B 10 0 (0) 1 (10) 8 (80) 0 (0) 
Temporalis 
A 18 6 (33.3) 7 (38.9) 4 (22.2) 1 (5.6) 
P=0.865 
B 10 3 (30) 4 (40) 3 (30) 0 (0) 
 
  Painful site during AMO 
   None TMJ Muscle 
TMJ & 
muscle 
Group n n (%) n (%) n (%) n (%) 
Preinjection 
A 17
a 
8 (47.1) 5 (29.4) 4 (23.5) 0 (0) 
P=0.494 
B 10 3 (30) 4 (40) 2 (20) 1 (10) 
Postinjection 
A 16
b 
8 (50.0) 6 (37.5) 2 (12.5) 0 (0) 
P=0.301 
B 8
c 
2 (25.0) 3 (37.5) 3 (37.5) 0 (0) 
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Table 7. Group comparison of degenerative or pathologic bony change in the 
condylar head observed in CT/CBCT images of the TMJ at preinjection 
 
*: degenerative or pathologic bony change includes bony irregularity(erosion) or  
flattening of condylar bony surface, osteophyte formation, thickening of articular 
surface(osteosclerosis) and subchondral cyst in the subarticular bone (Okeson, 2013, 
208-209) 
 
 
 
Table 8. Group comparison of subjective (self-aware or heard by others) 
parafunctional habits (clenching and bruxism) during daytime and/or nighttime  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9. Group comparison of the degree of objective cheek and tongue ridging 
at preinjection 
 
*: the only significant different factor is cheek ridging   
  Condylar head 
   No image Normal Bony change* 
Group n n n (%) n (%) 
A 18 3 8 (53.3) 7 (46.7) 
P=0.210 
B 10 1 2 (22.2) 7 (77.8) 
  Subjective parafunctional habits 
   No Yes 
Group n n (%) n (%) 
A 18 3 (16.7) 15 (83.3) 
P=0.286 
B 10 0 (0) 10 (100) 
 
  Degree 
   None Mild Moderate Severe 
Group n n (%) n (%) n (%) n (%) 
Cheek 
ridging 
A 18 0 (0) 13 (72.2) 5 (27.8) 0 (0) 
P=0.022* 
B 10 1 (10) 2 (20) 7 (70) 0 (0) 
Tongue 
ridging 
A 18 1 (5.6) 12 (66.7) 5 (27.8) 0 (0) 
P=0.050 
B 10 0 (0) 3 (30) 7 (70) 0 (0) 
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V. DISCUSSION 
 
Factors that can increase the joint loading are susceptible to causing changes 
in the articular surface and inducing the friction (Okeson, 2013, 155) or 
resistance of disc-condyle movement, and then increasing the joint sounds.   
This study looked at patients who received BoNT injection into the 
masticatory muscles and divided them into two groups: patients who ceased 
producing TMJ sounds were compared to those who continued producing TMJ 
sounds following BoNT injection. The two groups were then compared for 
factors that may affect joint loading. Such factors included total dose of BoNT 
injected, site and degree of pain, occlusion, face squareness, degenerative bony 
change in the condylar head observed in CT/CBCT images of the TMJ and 
parafunctional habits between groups.    
TMJ sounds can disappear as the degree of mouth opening decreases, or can 
newly appear as the degree of mouth opening increases, depending on the 
location from which the sound originates. In the present study, no significant 
differences were found between groups A and B in the degree of AMO at pre- 
and postinjection and thus, the disappearance of sounds was probably not due to 
a reduction in the degree of AMO.  
BoNT is a neurotoxic protein that prevents the release of acetylcholine in 
presynaptic terminals of neuromuscular junctions (CDER, 2014; Kurtoglu et al., 
2008), and subsequently interrupts neuromuscular transmission. This partial 
chemical denervation of the muscle causes muscle relaxation and, eventually 
paralysis (CDER, 2014). The degree of joint loading may differ according to the 
dose of BoNT, determining the paralysis of the injected muscles. However, no 
significant difference was observed between the groups in total dose of BoNT 
injected into the masseter and temporalis muscles, suggesting that the dose of 
BoNT does not play a role in the reduction of joint sounds.   
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There were no significant differences between the groups in degree of OJ and 
OB, total number of CO stops, and bilateral balance of CO stops which were 
related to the static occlusion. Changes in CO stops at pre- and postinjection 
could not be evaluated due to the lack of records. When only the static 
relationship of teeth was assessed, no insight was given into the risk for TMD; 
however when load was applied, dental malocclusion could affect the force 
distribution (Okeson, 2013, 119). BoNT injection into masticatory muscles could 
possibly result in the precise occlusal change through muscle paralysis, inducing 
changes in the joint sounds and loading. Change in acute sensory input may also 
cause changes in joint loading by prompting protective co-contraction (muscle 
splinting). Therefore, evaluation of occlusal change before and after BoNT 
injection using occlusal analysis system such as T-scan could be a meaningful 
trial to indentify the relationship with reducing sound.  
Anatomic muscular and skeletal pattern may be associated with force 
distribution, while face squareness was found to have no remarkable association 
with reductions in joint sounds. 
There were also no significant differences between the two groups in the 
location of subjective pain during AMO and in the degree of tenderness to 
palpation on the masseter and temporalis muscles, and TMJ. Constant deep pain 
input can increase joint loading by producing protective co-contraction, 
demonstrating increased muscle activity (Okeson, 2013, 109, 131). However, 
data on the continuity of pain could not be retrieved from the records. If it 
eliminates continuous spontaneous pain, BoNT injection probably contributes to 
the reduction in joint sounds, decreasing protective co-contraction.    
There was no significant difference in comparing degenerative or pathologic 
bony change in the condylar head observed in CT/CBCT images of the TMJ 
which was analyzed as a positive indication of joint loading. The amount or 
duration of overloading affects bony changes. However, the existence of factors 
inducing overloading does not always cause bony change. Furthermore, 
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radiographic changes are seen only in later stages of osteoarthritis and may not 
reflect recent stages accurately (Okeson, 2013, 155). Therefore, it is 
insufficient to determine whether these stages are progressive or adaptive or 
whether overloading exists at the moment of taking CT/CBCT image.  
One of the most common factors that can lead to joint overloading is 
microtrauma associated with muscle hyperactivity including bruxism or 
clenching (Okeson, 2013, 147). History of clenching and bruxism during daytime 
and/or nighttime was examined before injection. This did not necessarily mean 
that patients had such habits at the time of injection. Furthermore, as these 
activities often occurred at subconscious levels and were easy to be 
underestimated, the severity of the parafunctional habits could not be assessed. 
On the other hand, the degree of cheek ridging is considered as objective 
findings related to parafunctional habits (Okeson, 2013, 110) and can guess the 
severity of the habits. A greater severity in the degree of cheek ridging was 
associated with parafunctional habits that were more frequent or intense. This 
was the only factor that differed significantly between the groups. 
The following mechanism can be hypothesized as underlying the reduction in 
TMJ sounds induced by BoNT injection into masticatory muscles. The sound 
reduction could result from reduced pressure inside the joint space through 
weakening of the intensity of contractions during parafunctional habits such as 
clenching or bruxism and even during functional activities and resting state by 
the paralyzing effect of BoNT. This would be expected to decrease the stresses 
on the TMJ and related tissues (Freund et al., 2000). Freund et al. (2000) 
injected BoNT into the masseter and temporalis muscles to treat TMD in an 
uncontrolled study, and reported that the maximum voluntary clenching 
decreased from after 2 weeks to after 8 weeks. Kortoglu et al. (2008) 
conducted a prospective, randomized, double-blind, placebo-controlled study, 
and concluded that injecting BoNT into the bilateral masseter and anterior 
temporalis muscles decreased the muscle action potentials as measured by 
 17 
electromyography in the rest position after 14 days and at maximal clenching 
after 14-28 days. Shim et al. (2014) evaluated the effect of BoNT injection on 
sleep bruxism using video-polysomnography. The results showed that injecting 
BoNT into the masseter and temporalis muscles did not change the occurrence 
of rhythmic masticatory muscle activity episodes, but it did reduce the intensity 
of the muscle contractions.  
Tongue ridging is a similar parameter associated with parafunctional habits. 
However, there was no significant difference in the degree of tongue ridging. 
Anatomical differences such as macroglossia (large tongue beside the dental 
arch) can produce tongue ridging regardless of the parafunctional habits. Chart 
records were insufficient in attaining such conclusions. 
From this study, it is considered that joint sounds are easier to decrease in 
people who have more severe parafunctional habits (in terms of their frequency 
of occurrence or intensity), showing moderate to severe cheek ridging as the 
effect of weakening the intensity of the muscle contraction by BoNT injection 
would be more apparent.  
This study was a retrospective review that was subject to several limitations:  
1. The dose of BoNT injected was not uniform.  
2. There were differences in injection methods (number of injected muscles and 
injection location), valuation criteria for determining the degree of cheek/tongue 
ridging, and follow-up periods according to the operators (clinician).  
3. Other confounding factors such as other types of conservative treatment 
(e.g., medication, splint therapy, and physical therapy) and influencing factors 
(e.g., emotional stress and, behavior control) could not be controlled.  
4. The disc displacement or dislocation was not confirmed using MRI before or 
after the injection.  
5. The sample was small.  
Future well-controlled prospective studies are needed to address the 
limitations of the present study.  
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VI. CONCLUSION 
 
This study reviewed the chart of patients who received BoNT injection into 
their masseter and/or temporalis muscles for the treatment of myofascial pain, 
parafunctional habits such as bruxism and clenching, and chronic migraine. And   
patients who ceased producing TMJ sounds were compared to those who 
continued producing TMJ sounds following BoNT injection. The results showed 
that only the degree of cheek ridging differed significantly between the groups. 
This suggests that weakening the intensity of masticatory muscle contraction by 
BoNT injection could be responsible for reducing TMJ sounds by decreasing the 
joint loading or microtrauma. BoNT injection into the masseter and/or temporalis 
muscles may reduce distressing TMJ sounds and serve as an alternative 
treatment for patients who have moderate to severe cheek ridging. However, 
since this study was subject to several limitations, the results need to be 
confirmed in future well-controlled prospective studies.  
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국문요약 
 
저작근에 보툴리눔 독소 주사 후 측두하악관절음의 변화 
 
<지도 김 성 택 교수> 
연세대학교 대학원 치의학과 
정 아 영 
 
단순관절음, 거대관절음, 염발음과 같은 측두하악관절음은 통증이 없거나 하악의 
운동에 제한을 주지 않는다면 특별히 치료해야 할 필요가 없고, 일반적으로 보존적인 
치료로 사라지지 않음에도 관절음 자체에 의해 스트레스를 받는 환자들이 일부 존재한다. 
이 연구의 목적은 교근 및 측두근과 같은 저작근에 보툴리눔 독소를 주사한 이후 주사 
전에 가지고 있던 관절음에 변화가 있는지를 추적하고, 군간의 비교를 통해서 관절음의 
소실과 관련된 요인을 확인하는 데에 있다.  
주사 전에 관절음이 관찰되고, 근막통증, 이갈이와 이악물기와 같은 비기능적 습관 
혹은 만성편두통을 치료하기 위해 교근/측두근에 보툴리눔 독소 주사요법을 시행한 
28 명의 환자의 진료 기록을 후향적으로 분석하여 주사 후에 소리가 잔존하는 군 (A 군, 
18 명) 과 소리가 사라진 군 (B 군, 10 명) 간에 여러 요인을 비교하였다. 대부분 군간 
비교에서 유의한 차이를 나타내지 않았으나, 유일하게 협점막 압흔의 정도만이 유의한 
차이를 보였는데, 이는 보툴리눔 독소를 저작근에 주입함으로써 저작근의 수축 강도를 
약화시키고, 결과적으로 관절에 가해지는 부하나 미세 외상을 감소시킨 결과로 추측된다. 
이를 바탕으로 관절음으로 인한 고통을 호소하는 환자들 중에서, 중등도에서 심도의 
협점막 압흔을 보이는 경우에 저작근에 보툴리눔 독소를 주사하면 관절음이 줄어들 
가능성이 있으므로 임상적으로 적용할 수 있을 것으로 사료된다. 그러나, 이 연구가 여러 
가지 한계점을 가지고 있어, 추후 잘 설계된 전향 연구를 통한 확인이 필요하다.  
 
 
핵심되는 말: 보툴리눔 독소, 저작근, 측두하악관절음, 협점막 압흔 
